{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T03:32:28Z","timestamp":1795059148291,"version":"4.10.2"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T00:00:00Z","timestamp":1766448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T00:00:00Z","timestamp":1769472000000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["CRU 5002"],"award-info":[{"award-number":["CRU 5002"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Mutant Ras oncoproteins, particularly KRAS, are among the most prevalent drivers of cancer. Small-molecule KRAS inhibitors have emerged as promising cancer therapeutics, yet resistance development remains a major hurdle. To overcome this challenge, we explored rational combination strategies aimed at enhancing therapeutic efficacy and durability. We show that the KRAS-G12C inhibitor Sotorasib synergizes with the CDK4\/6 inhibitor Palbociclib to eliminate pancreatic ductal adenocarcinoma (PDAC) cells and organoids harboring KRAS-G12C mutations. This synergy was especially pronounced following drug washout, indicating a durable cellular response. Similar synergistic effects were observed in non-small-cell lung cancer (NSCLC) cells. Additionally, the KRAS-G12D inhibitor MRTX1133 cooperated with Palbociclib to suppress growth of KRAS-G12D-mutant PDAC cells. Mechanistically, the combinations induced sustained cell cycle arrest, marked by reduced RB phosphorylation, decreased E2F1 expression, and increased levels of CDKN1B\/p27. Deletion of\n                    <jats:italic>CDKN1B<\/jats:italic>\n                    largely reversed the growth-inhibitory effect, highlighting its essential role in mediating the observed synergy. In an orthotopic, immunocompetent mouse model of PDAC, MRTX1133 significantly reduced tumor growth and extended survival; however, despite its ability to suppress RB phosphorylation, Palbociclib failed to enhance these effects. Single-cell RNA sequencing suggested that Palbociclib treatment induces tumor vascularization, perhaps contributing to the lack of drug synergy observed in vivo. In summary, our findings demonstrate the therapeutic potential of enhancing cell cycle restriction point activation in KRAS inhibitor-based therapies, while emphasizing the importance of placing combination therapies into a suitable context.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08362-w","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:45:35Z","timestamp":1766486735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Simultaneous targeting of KRAS and CDK4 synergistically induces durable growth arrest in pancreatic cancer cells"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-5625-7251","authenticated-orcid":false,"given":"Maj-Britt","family":"Paulsohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8510-2502","authenticated-orcid":false,"given":"Klara Henrike","family":"Frahnert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5780-5307","authenticated-orcid":false,"given":"Denise","family":"Schl\u00f6sser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joana","family":"Oschwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waltraut","family":"Kopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2098-6623","authenticated-orcid":false,"given":"Xin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constanza","family":"Tapia Contreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi","family":"Danieli-Mackay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Ludewig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bleyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1840-4508","authenticated-orcid":false,"given":"G\u00fcnter","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-1291","authenticated-orcid":false,"given":"Elisabeth","family":"Hessmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5052-3967","authenticated-orcid":false,"given":"Matthias","family":"Dobbelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,23]]},"reference":[{"key":"8362_CR1","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/nrc3106","volume":"11","author":"Y Pylayeva-Gupta","year":"2011","unstructured":"Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 2011;11:761\u201374.","journal-title":"Nat Rev Cancer"},{"key":"8362_CR2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/297474a0","volume":"297","author":"LF Parada","year":"1982","unstructured":"Parada LF, Tabin CJ, Shih C, Weinberg RA. Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature. 1982;297:474\u20138.","journal-title":"Nature"},{"key":"8362_CR3","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969\u201383.","journal-title":"Nat Med"},{"key":"8362_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00334-z","volume":"6","author":"JK Lee","year":"2022","unstructured":"Lee JK, Sivakumar S, Schrock AB, Madison R, Fabrizio D, Gjoerup O, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;6:91.","journal-title":"NPJ Precis Oncol"},{"key":"8362_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","volume":"19","author":"AR Moore","year":"2020","unstructured":"Moore AR, Rosenberg SC, McCormick F, Malek S. RAS-targeted therapies: is the undruggable drugged? Nat Rev Drug Discov. 2020;19:533\u201352.","journal-title":"Nat Rev Drug Discov"},{"key":"8362_CR6","first-page":"2626","volume":"56","author":"GC Prendergast","year":"1996","unstructured":"Prendergast GC, Davide JP, Lebowitz PF, Wechsler-Reya R, Kohl NE. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors. Cancer Res. 1996;56:2626\u201332.","journal-title":"Cancer Res"},{"key":"8362_CR7","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"8362_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor. Cell. 2018;172:578\u201389.e517.","journal-title":"Cell"},{"key":"8362_CR9","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durm GA, Shapiro GI, et al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N Engl J Med. 2020;383:1207\u201317.","journal-title":"N Engl J Med"},{"key":"8362_CR10","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for lung cancers with KRAS p.G12C mutation. N Engl J Med. 2021;384:2371\u201381.","journal-title":"N Engl J Med"},{"key":"8362_CR11","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"8362_CR12","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41571-022-00671-9","volume":"19","author":"SR Punekar","year":"2022","unstructured":"Punekar SR, Velcheti V, Neel BG, Wong KK. The current state of the art and future trends in RAS-targeted cancer therapies. Nat Rev Clin Oncol. 2022;19:637\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"8362_CR13","doi-asserted-by":"crossref","unstructured":"Isermann T, Sers C, Der CJ, Papke B KRAS inhibitors: resistance drivers and combinatorial strategies. Trends Cancer. 2024;11:91\u2013116.","DOI":"10.1016\/j.trecan.2024.11.009"},{"key":"8362_CR14","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","volume":"28","author":"S Goel","year":"2018","unstructured":"Goel S, DeCristo MJ, McAllister SS, Zhao JJ. CDK4\/6 inhibition in cancer: beyond cell cycle arrest. Trends Cell Biol. 2018;28:911\u201325.","journal-title":"Trends Cell Biol"},{"key":"8362_CR15","doi-asserted-by":"publisher","first-page":"4760","DOI":"10.1158\/1078-0432.CCR-15-1185","volume":"21","author":"JA Beaver","year":"2015","unstructured":"Beaver JA, Amiri-Kordestani L, Charlab R, Chen W, Palmby T, Tilley A, et al. FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res. 2015;21:4760\u20136.","journal-title":"Clin Cancer Res"},{"key":"8362_CR16","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nrclinonc.2016.26","volume":"13","author":"B O\u2019Leary","year":"2016","unstructured":"O\u2019Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4\/6 inhibitors. Nat Rev Clin Oncol. 2016;13:417\u201330.","journal-title":"Nat Rev Clin Oncol"},{"key":"8362_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01510-6","volume":"24","author":"AC Watt","year":"2022","unstructured":"Watt AC, Goel S. Cellular mechanisms underlying response and resistance to CDK4\/6 inhibitors in the treatment of hormone receptor-positive breast cancer. Breast Cancer Res. 2022;24:17.","journal-title":"Breast Cancer Res"},{"key":"8362_CR18","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/nrc1691","volume":"5","author":"WG Kaelin Jr","year":"2005","unstructured":"Kaelin WG Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat Rev Cancer. 2005;5:689\u201398.","journal-title":"Nat Rev Cancer"},{"key":"8362_CR19","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","volume":"24","author":"N Perurena","year":"2024","unstructured":"Perurena N, Situ L, Cichowski K. Combinatorial strategies to target RAS-driven cancers. Nat Rev Cancer. 2024;24:316\u201337.","journal-title":"Nat Rev Cancer"},{"key":"8362_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57417-z","volume":"14","author":"K Cheng","year":"2024","unstructured":"Cheng K, Zhou Z, Chen Q, Chen Z, Cai Y, Cai H, et al. CDK4\/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma. Sci Rep. 2024;14:8389.","journal-title":"Sci Rep"},{"key":"8362_CR21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1158\/0008-5472.CAN-22-0391","volume":"83","author":"CM Goodwin","year":"2023","unstructured":"Goodwin CM, Waters AM, Klomp JE, Javaid S, Bryant KL, Stalnecker CA, et al. Combination therapies with CDK4\/6 inhibitors to treat KRAS-mutant pancreatic cancer. Cancer Res. 2023;83:141\u201357.","journal-title":"Cancer Res"},{"key":"8362_CR22","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-19-1043","volume":"20","author":"BA Willobee","year":"2021","unstructured":"Willobee BA, Gaidarski AA, Dosch AR, Castellanos JA, Dai X, Mehra S, et al. Combined blockade of MEK and CDK4\/6 pathways induces senescence to improve survival in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2021;20:1246\u201356.","journal-title":"Mol Cancer Ther"},{"key":"8362_CR23","doi-asserted-by":"crossref","unstructured":"Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, et al. KRAS(G12C) inhibition produces a driver-limited state revealing collateral dependencies. Sci Signal. 2019;12:eaaw9450.","DOI":"10.1126\/scisignal.aaw9450"},{"key":"8362_CR24","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41375-021-01475-z","volume":"36","author":"S Adamia","year":"2022","unstructured":"Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, et al. Combination therapy targeting Erk1\/2 and CDK4\/6i in relapsed refractory multiple myeloma. Leukemia. 2022;36:1088\u2013101.","journal-title":"Leukemia"},{"key":"8362_CR25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41388-023-02900-6","volume":"43","author":"K Jagirdar","year":"2024","unstructured":"Jagirdar K, Portuallo ME, Wei M, Wilhide M, Bravo Narula JA, Robertson BM, et al. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4\/6 inhibitor resistance in acral lentiginous melanoma. Oncogene. 2024;43:395\u2013405.","journal-title":"Oncogene"},{"key":"8362_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-68950-y","volume":"10","author":"T Pantsar","year":"2020","unstructured":"Pantsar T. KRAS(G12C)-AMG 510 interaction dynamics revealed by all-atom molecular dynamics simulations. Sci Rep. 2020;10:11992.","journal-title":"Sci Rep"},{"key":"8362_CR27","doi-asserted-by":"crossref","unstructured":"Tapia Contreras C, Falke JD, Seifert DM, Schneider C, Krau\u00df L, Fang X, et al. KRAS(G) (12C)-inhibitor-based combination therapies for pancreatic cancer: insights from drug screening. Mol Oncol. 2024;19:295\u2013310.","DOI":"10.1002\/1878-0261.13725"},{"key":"8362_CR28","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor. Nat Med. 2022;28:2171\u201382.","journal-title":"Nat Med"},{"key":"8362_CR29","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/acs.jmedchem.1c01688","volume":"65","author":"X Wang","year":"2022","unstructured":"Wang X, Allen S, Blake JF, Bowcut V, Briere DM, Calinisan A, et al. Identification of MRTX1133, a noncovalent, potent, and selective KRAS(G12D) inhibitor. J Med Chem. 2022;65:3123\u201333.","journal-title":"J Med Chem"},{"key":"8362_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/nar\/gkv927","volume":"44","author":"M Fischer","year":"2016","unstructured":"Fischer M, Quaas M, Steiner L, Engeland K. The p53-p21-DREAM-CDE\/CHR pathway regulates G2\/M cell cycle genes. Nucleic Acids Res. 2016;44:164\u201374.","journal-title":"Nucleic Acids Res"},{"key":"8362_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/cdd.2017.172","volume":"25","author":"K Engeland","year":"2018","unstructured":"Engeland K. Cell cycle arrest through indirect transcriptional repression by p53: I have a DREAM. Cell Death Differ. 2018;25:114\u201332.","journal-title":"Cell Death Differ"},{"key":"8362_CR32","doi-asserted-by":"crossref","unstructured":"Rouillard AD, Gundersen GW, Fernandez NF, Wang Z, Monteiro CD, McDermott MG, et al. The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins. Database. 2016;2016:baw100.","DOI":"10.1093\/database\/baw100"},{"key":"8362_CR33","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0092-8674(94)90572-X","volume":"78","author":"K Polyak","year":"1994","unstructured":"Polyak K, Lee MH, Erdjument-Bromage H, Koff A, Roberts JM, Tempst P, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell. 1994;78:59\u201366.","journal-title":"Cell"},{"key":"8362_CR34","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1007\/s12032-025-02973-1","volume":"42","author":"J Gupta","year":"2025","unstructured":"Gupta J, Saeed BI, Bishoyi AK, Alkhathami AG, Asliddin S, Nathiya D, et al. From cell cycle control to cancer therapy: exploring the role of CDK1 and CDK2 in tumorigenesis. Med Oncol. 2025;42:422.","journal-title":"Med Oncol"},{"key":"8362_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116140","volume":"44","author":"ES Knudsen","year":"2025","unstructured":"Knudsen ES, Witkiewicz AK, Sanidas I, Rubin SM. Targeting CDK2 for cancer therapy. Cell Rep. 2025;44:116140.","journal-title":"Cell Rep"},{"key":"8362_CR36","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.jcmgh.2023.01.015","volume":"15","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang X, Hamdan FH, Likhobabina A, Patil S, Aperdannier L, et al. NFATc1 is a central mediator of EGFR-induced ARID1A chromatin dissociation during acinar cell reprogramming. Cell Mol Gastroenterol Hepatol. 2023;15:1219\u201346.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"8362_CR37","doi-asserted-by":"publisher","first-page":"1606","DOI":"10.1016\/j.ccell.2023.07.002","volume":"41","author":"KK Mahadevan","year":"2023","unstructured":"Mahadevan KK, McAndrews KM, LeBleu VS, Yang S, Lyu H, Li B, et al. KRAS(G12D) inhibition reprograms the microenvironment of early and advanced pancreatic cancer to promote FAS-mediated killing by CD8(+) T cells. Cancer cell. 2023;41:1606\u201320.e1608.","journal-title":"Cancer cell"},{"key":"8362_CR38","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1158\/2159-8290.CD-22-1066","volume":"13","author":"SB Kemp","year":"2023","unstructured":"Kemp SB, Cheng N, Markosyan N, Sor R, Kim IK, Hallin J, et al. Efficacy of a small-molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer. Cancer Discov. 2023;13:298\u2013311.","journal-title":"Cancer Discov"},{"key":"8362_CR39","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cell.2020.03.008","volume":"181","author":"Ruscetti","year":"2020","unstructured":"Ruscetti, Morris M, JPt, Mezzadra R, Russell J, Leibold J, et al. Senescence-induced vascular remodeling creates therapeutic vulnerabilities in pancreas cancer. Cell. 2020;181:424\u201341.e421.","journal-title":"Cell"},{"key":"8362_CR40","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1158\/1535-7163.MCT-20-1126","volume":"20","author":"KW Nassar","year":"2021","unstructured":"Nassar KW, Hintzsche JD, Bagby SM, Espinoza V, Langou\u00ebt-Astri\u00e9 C, Amato CM, et al. Targeting CDK4\/6 represents a therapeutic vulnerability in acquired BRAF\/MEK inhibitor-resistant melanoma. Mol Cancer Ther. 2021;20:2049\u201360.","journal-title":"Mol Cancer Ther"},{"key":"8362_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.661737","volume":"12","author":"EJ Lelliott","year":"2021","unstructured":"Lelliott EJ, McArthur GA, Oliaro J, Sheppard KE. Immunomodulatory effects of BRAF, MEK, and CDK4\/6 inhibitors: implications for combining targeted therapy and immune checkpoint blockade for the treatment of melanoma. Front Immunol. 2021;12:661737.","journal-title":"Front Immunol"},{"key":"8362_CR42","doi-asserted-by":"publisher","first-page":"39595","DOI":"10.18632\/oncotarget.9153","volume":"7","author":"MS Lee","year":"2016","unstructured":"Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, et al. Efficacy of the combination of MEK and CDK4\/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget. 2016;7:39595\u2013608.","journal-title":"Oncotarget"},{"key":"8362_CR43","doi-asserted-by":"publisher","first-page":"3335","DOI":"10.1158\/0008-5472.CAN-22-0198","volume":"82","author":"AV Sorokin","year":"2022","unstructured":"Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, et al. Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4\/6. Cancer Res. 2022;82:3335\u201344.","journal-title":"Cancer Res"},{"key":"8362_CR44","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nrd4389","volume":"13","author":"AD Cox","year":"2014","unstructured":"Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible? Nat Rev Drug Discov. 2014;13:828\u201351.","journal-title":"Nat Rev Drug Discov"},{"key":"8362_CR45","doi-asserted-by":"crossref","unstructured":"Waters AM, Der CJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb Perspect Med. 2018;8:a031435.","DOI":"10.1101\/cshperspect.a031435"},{"key":"8362_CR46","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1158\/2159-8290.CD-24-1425","volume":"15","author":"C Broderick","year":"2025","unstructured":"Broderick C, Mezzadra R, Sisso EM, Mbuga F, Raghulan R, Chaves-Perez A, et al. A RAS(ON) multi-selective inhibitor combination therapy triggers long-term tumor control through senescence-associated tumor-immune equilibrium in pancreatic ductal adenocarcinoma. Cancer Discov. 2025;15:1717\u201339.","journal-title":"Cancer Discov"},{"key":"8362_CR47","doi-asserted-by":"publisher","first-page":"7005","DOI":"10.1073\/pnas.1817415116","volume":"116","author":"H Yoon","year":"2019","unstructured":"Yoon H, Kim M, Jang K, Shin M, Besser A, Xiao X, et al. p27 transcriptionally coregulates cJun to drive programs of tumor progression. Proc Natl Acad Sci USA. 2019;116:7005\u201314.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8362_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms7744","volume":"6","author":"AK Witkiewicz","year":"2015","unstructured":"Witkiewicz AK, McMillan EA, Balaji U, Baek G, Lin WC, Mansour J, et al. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015;6:6744.","journal-title":"Nat Commun"},{"key":"8362_CR49","doi-asserted-by":"publisher","first-page":"e43192","DOI":"10.1371\/journal.pone.0043192","volume":"7","author":"WS Liang","year":"2012","unstructured":"Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, et al. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS ONE. 2012;7:e43192.","journal-title":"PLoS ONE"},{"key":"8362_CR50","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/nrd4201","volume":"13","author":"M Dobbelstein","year":"2014","unstructured":"Dobbelstein M, Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov. 2014;13:179\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"8362_CR51","doi-asserted-by":"crossref","unstructured":"Orlen MI, Vostrejs WP, Sor R, McDevitt JC, Kemp SB, Kim IK, et al. T-cell dependency of tumor regressions and complete responses with RAS(ON) multi-selective inhibition in preclinical models of PDAC. Cancer Dis. 2025;15:1697\u20131716.","DOI":"10.1158\/2159-8290.CD-24-1475"},{"key":"8362_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104119","volume":"353","author":"LQ Fu","year":"2020","unstructured":"Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119.","journal-title":"Cell Immunol"},{"key":"8362_CR53","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","volume":"8","author":"ZL Liu","year":"2023","unstructured":"Liu ZL, Chen HH, Zheng LL, Sun LP, Shi L. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8:198.","journal-title":"Signal Transduct Target Ther"},{"key":"8362_CR54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1053\/j.seminoncol.2024.01.002","volume":"50","author":"D Wekking","year":"2023","unstructured":"Wekking D, Lambertini M, Dess\u00ec M, Denaro N, Bardanzellu F, Garrone O, et al. CDK4\/6 inhibitors in the treatment of metastatic breast cancer: focus on toxicity and safety. Semin Oncol. 2023;50:131\u20139.","journal-title":"Semin Oncol"},{"key":"8362_CR55","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1080\/14737140.2021.1852934","volume":"21","author":"CE Onesti","year":"2021","unstructured":"Onesti CE, Jerusalem G. CDK4\/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. a systematic review and meta-analysis. Expert Rev Anticancer Ther. 2021;21:283\u201398.","journal-title":"Expert Rev Anticancer Ther"},{"key":"8362_CR56","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ccell.2025.02.006","volume":"43","author":"CL Palmer","year":"2025","unstructured":"Palmer CL, Boras B, Pascual B, Li N, Li D, Garza S, et al. CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. Cancer Cell. 2025;43:464\u201381.e414.","journal-title":"Cancer Cell"},{"key":"8362_CR57","unstructured":"Neuwirth E RColorBrewer: ColorBrewer palettes. 1.1-3 ed. R package: https:\/\/cran.r-project.org\/web\/packages\/RColorBrewer\/index.html; 2022."},{"key":"8362_CR58","unstructured":"Wickham H, Chang W, Henry L, Pedersen T, Takahashi K, Wilke C, et al. ggplot2: create elegant data visualisations using the grammar of graphics. R package: https:\/\/cran.r-project.org\/web\/packages\/ggplot2\/index.html; 2022."},{"key":"8362_CR59","unstructured":"Warnes GR, Bolker B, Bonebakker L, Gentleman R, Huber W, Liaw A, et al. gplots: various R programming tools for plotting data. R package: https:\/\/CRAN.R-project.org\/package=gplots; 2022."},{"key":"8362_CR60","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1093\/bioinformatics\/btx162","volume":"33","author":"A Ianevski","year":"2017","unstructured":"Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose-response matrix data. Bioinformatics. 2017;33:2413\u20135.","journal-title":"Bioinformatics"},{"key":"8362_CR61","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114610","volume":"43","author":"J Jansen","year":"2024","unstructured":"Jansen J, Bohnsack KE, Bohlken-Fascher S, Bohnsack MT, Dobbelstein M. The ribosomal protein L22 binds the MDM4 pre-mRNA and promotes exon skipping to activate p53 upon nucleolar stress. Cell Rep. 2024;43:114610.","journal-title":"Cell Rep"},{"key":"8362_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: Open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"8362_CR63","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42:293\u2013304.","journal-title":"Nat Biotechnol"},{"key":"8362_CR64","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cels.2019.06.004","volume":"9","author":"Y Tan","year":"2019","unstructured":"Tan Y, Cahan P. SingleCellNet: a computational tool to classify single cell RNA-seq data across platforms and across species. Cell Syst. 2019;9:207\u201313.e202.","journal-title":"Cell Syst"},{"key":"8362_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09234-6","volume":"10","author":"Y Zhou","year":"2019","unstructured":"Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10:1523.","journal-title":"Nat Commun"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08362-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08362-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T18:02:47Z","timestamp":1769536967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08362-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,23]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8362"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08362-w","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,23]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"129"}}